Neuroscience Insights,
Год журнала:
2024,
Номер
19
Опубликована: Янв. 1, 2024
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
a
novel
coronavirus,
emerged
in
December
2019,
sparking
global
health
crisis.
While
initially
recognized
as
illness,
it
has
become
evident
that
Coronavirus
disease
2019
(COVID-19)
also
affects
the
central
nervous
system.
This
comprehensive
review
focuses
on
neurological
manifestations
of
COVID-19
and
its
impact
patients
with
preexisting
disorders,
particularly
those
multiple
sclerosis
(MS)
receiving
disease-modifying
therapies.
Advancements
management,
including
vaccinations,
antiviral
therapy,
targeted
prophylaxis,
have
led
to
decline
incidence
severity
COVID-19.
Nevertheless,
significant
complications
persist,
advanced
MS,
who
are
highly
vulnerable
infectious
agents
like
SARS-CoV-2.
explores
evolving
understanding
MS
association
SARS-CoV-2,
encompassing
neuroinvasiveness,
pathogenesis,
severity,
outcomes.
Research
findings
reveal
substantial
implications
for
some
COVID-19,
potential
risk
relapse
severity.
A
notable
proportion
experiencing
may
manifest
new
symptoms,
experience
exacerbation
existing
or
encounter
both
simultaneously,
underscoring
diverse
effects
virus.
vaccination
therapeutics
mitigated
overall
impact,
specific
subgroups,
especially
anti-CD20
therapy
disability,
remain
at
higher
risk,
necessitating
ongoing
vigilance
tailored
care.
Journal of Clinical Virology Plus,
Год журнала:
2024,
Номер
4(2), С. 100180 - 100180
Опубликована: Апрель 24, 2024
This
study
aimed
to
evaluate
the
impact
of
remdesivir,
alone
or
in
combination
with
corticosteroids,
on
time
death
COVID-19
patients.
retrospective
cohort
was
conducted
between
March
20,
2020,
and
18,
2021,
5318
patients
confirmed
at
three
tertiary
educational
hospitals
Tehran,
Iran.
The
treated
group
consisted
who
received
either
while
untreated
included
infected
did
not
receive
these
treatments.
two
groups
were
matched
by
propensity
score
matching
method,
which
adjusted
for
92
confounding
factors
such
as
demographic,
sign
symptom,
clinical,
treatment-related
factors,
provide
balanced
covariates
groups.
Of
4,322
patients,
791
remdesivir
694
combined
corticosteroids.
Among
456
male,
mean
(±standard
deviation)
age
59.52±16.49
a
median
hospitalization
stay
8
(interquartile
range:
5–13)
days.
After
applying
nearest
neighbor
there
no
significant
differences
found
hazard
those
treatment
(hazard
ratio:
0.94;
95
%
confidence
interval:
0.76,
1.16).
In
addition,
corticosteroids
associated
reduced
1.00;
0.80,
1.26).
significantly
longer
(alone/combined
corticosteroids)
compared
group,
both
before
after
matching.
No
association
observed
among
However,
stays
receiving
group.
Neuroscience Insights,
Год журнала:
2024,
Номер
19
Опубликована: Янв. 1, 2024
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
a
novel
coronavirus,
emerged
in
December
2019,
sparking
global
health
crisis.
While
initially
recognized
as
illness,
it
has
become
evident
that
Coronavirus
disease
2019
(COVID-19)
also
affects
the
central
nervous
system.
This
comprehensive
review
focuses
on
neurological
manifestations
of
COVID-19
and
its
impact
patients
with
preexisting
disorders,
particularly
those
multiple
sclerosis
(MS)
receiving
disease-modifying
therapies.
Advancements
management,
including
vaccinations,
antiviral
therapy,
targeted
prophylaxis,
have
led
to
decline
incidence
severity
COVID-19.
Nevertheless,
significant
complications
persist,
advanced
MS,
who
are
highly
vulnerable
infectious
agents
like
SARS-CoV-2.
explores
evolving
understanding
MS
association
SARS-CoV-2,
encompassing
neuroinvasiveness,
pathogenesis,
severity,
outcomes.
Research
findings
reveal
substantial
implications
for
some
COVID-19,
potential
risk
relapse
severity.
A
notable
proportion
experiencing
may
manifest
new
symptoms,
experience
exacerbation
existing
or
encounter
both
simultaneously,
underscoring
diverse
effects
virus.
vaccination
therapeutics
mitigated
overall
impact,
specific
subgroups,
especially
anti-CD20
therapy
disability,
remain
at
higher
risk,
necessitating
ongoing
vigilance
tailored
care.
